Yosuke Maezawa, Manato Taguchi, Takeshi Kawakami, Toshihide Inui, Shinichiro Okauchi, Takeshi Numata, Toshihiro Shiozawa, Kunihiko Miyazaki, Ryota Nakamura, Kesato Iguchi, Takeo Endo, Tohru Sakamoto, Hiroaki Satoh, Nobuyuki Hizawa
BACKGROUND/AIM: The median age of subjects in many clinical trials of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor conducted to date has been approximately 60 years. However, it is not uncommon to encounter EGFR gene-positive patients in their 70s or 80s. Based on information obtained from these clinical trials, EGFR gene-positive non-small cell lung cancer (NSCLC) patients are considered to be younger than EGFR-negative patients. In this study, we analyzed clinical data to identify whether this assumption is true...
April 2024: Anticancer Research